Antiangiogenic Treatment Concepts in Gynecologic Oncology by M. Eichbaum et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
22 
Antiangiogenic Treatment Concepts  
in Gynecologic Oncology 
M. Eichbaum, C. Mayer, E. Bischofs, J. Reinhardt, J. Thum and C. Sohn 
Departments of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, 
Germany 
1. Introduction 
Gynecologic malignancies count for about 80,000 of all new cancer diagnoses in women in 
the United States (Jemal et al., 2010). In the US almost 20,000 patients a year are diagnosed 
with epithelial ovarian cancer, 11,000 with cervical cancer and 42,000 with endometrial 
cancer (Jemal et al., 2010). A relevant part of these tumor situations are found in an early-
stage disease setting, for instance most of all newly diagnosed endometrial cancers. But 
frequently there is no possibility for an early-stage diagnosis and the tumor is already 
advanced when primarily detected, like in the majority of all cases with epithelial ovarian 
cancer (EOC). 
Though tumor biology and standard treatment concepts are different for all three entities, 
there is a common need for new therapeutic approaches to improve the patients’ outcome. 
Many preclinical studies have suggested that antiangiogenic strategies are beneficial against 
these cancers (Delli Carpini, 2010). One reason may be the fact that these tumors are able to 
form large single tumor nodulations during intraabdominal spread or local progression 
with hypoxic cores triggering tumor-associated neo-angiogenesis (Bryant et al., 2010). 
Furthermore, the frequently seen phenomenon of peritoneal carcinosis, closely related to 
gynecologic malignancies, induces angiogenesis to preserve nutritive supply to all 
metastatic tumor nodes (Fagotti et al., 2010, Figure 1).  
Since Folkman first proposed the strategy of targeting the tumor vasculature as a novel 
therapeutic strategy, considerable progress has been made to understand the underlying 
mechanisms of angiogenesis (Folkman, 1971). The control of angiogenesis is under the 
influence of both pro- and anti-angiogenesis factors. Of these, vascular endothelial growth 
factor (VEGF) and its family of receptors play a key role in the regulation of angiogenesis. 
The VEGF gene family consists of several members including placenta growth factor (PIGF), 
VEGF-A, VEGF-B, VEGF-C and VEGF-D, but VEGF-A (often referred to as VEGF) is the 
dominant protein (Ferrara, 2003). The VEGF receptor family consists of three members 
including VEGFR-1(Flt-1), VEGFR-2 (KDR or Flk-1), and VEGFR-3 (Flt-4). Given the key role 
of VEGF and its family of receptors in regulating angiogenesis, inhibitors of both VEGF and 
its receptors are actively being developed as anti-cancer therapies. To inhibit the VEGF 
pathway two different options are used: 
1. VEGF ligand inhibition by antibodies or soluble receptors 
2. VEGF receptor inhibition by tyrosine kinase inhibitor (TKIs) or receptor antibodies 
www.intechopen.com
 Current Cancer Treatment – Novel Beyond Conventional Approaches 
 
476 
Several further antiangiogenic targets beside the VEGF pathway are identified and explored 
(Figure 2). 
 
 
Fig. 1. Peritoneal carcinosis and Angiogenesis. 
The clinical evaluation of antiangiogenic drugs revealed new, unique toxicity profiles and 
potential side-effects, such as hypertension, proteinuria and GI-toxicities that have so far not 
been in the focus of the oncologist and need to be understood and closely considered during 
therapy. However, under careful and responsible advise most of the established and 
documented treatment concepts can be performed without difficulties. 
In summary, antiangiogenic drugs are reasonable and promising new therapeutic strategies 
under clinical investigation. Subsequently, current antiangiogenic treatment strategies 
against the three main gynecologic malignancies ovarian cancer, cervical cancer and 
endometrial cancer will be presented and discussed. 
2. Ovarian cancer 
2.1 Background 
In the US about 21,880 women a year develop a malignant tumour of the ovary. The 
incidence of ovarian carcinoma has remained unchanged in the last few decades. With more 
than 13,850 deaths, it is the fifth highest cause of cancer-related mortality in women. 
Symptoms of the disease usually develop at a very late stage. For this reason about 70% of 
patients are already in an advanced stage of the tumor at the time of diagnosis (FIGO III or 
 
www.intechopen.com
 Antiangiogenic Treatment Concepts in Gynecologic Oncology 
 
477 
 
Fig. 2. Molecular mechanisms in tumor-associated angiogenesis and main targets of current 
investigations. 
IV). Surgical tumor removal is the primary treatment. Whether and to what extent residual 
tumour formation is present postoperatively is the deciding factor in the subsequent 
prognosis for the patient. After surgery, chemotherapy involving paclitaxel plus carboplatin 
is generally indicated in the event of an initially advanced tumour stage (McGuire et al., 
1999; McGuire et al., 2001; Parmar et al., 2003). Despite improved surgical procedures and a 
high primary response to chemotherapy, about 70% of patients with advanced ovarian 
carcinoma develop a tumor relapse and die from the disease. 
Angiogenesis is a critical pathway in the development and progression of ovarian cancer. 
Therefore, identification and development of novel agents with limited toxicity that target 
mechanisms of tumor progression such as angiogenesis are of high priority. Data from 
numerous preclinical and clinical trials support the assumption of VEGF/VEGFR, PDGFR 
as well as FDGF as target molecules for the treatment of ovarian cancer (Burger, 2010). 
Beyond these currently intensively investigated targets, further antiagiogenic pathways are 
explored, such as angiopoetin or vascular disrupting agents (VDA) (Theo et al., 2010; 
Zweifel et al., 2011). 
Anti-angiogenic agents in investigational clinical trials 
Several anti-angiogenic agents are evaluated in investigational clinical trials to improve the 
therapy of recurrent and also primary ovarian cancer. Results from a number of phase I and 
phase II trials are available and also phase III trials have been performed and have led to 
first reported data, in particular the GOG 218 as well as the ICON-7-trial. 
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Table 1. Antiangiogenic drugs currently under investigation in EOC. 
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Bevacizumab  
The most clinical experiences have been collected targeting VEGF with the recombinant 
humanized monoclonal anti-VEGF antibody (bevacizumab, avastin®).  
Several phase II studies showed efficacy and tolerability as well in the palliative as in the 
adjuvant setting. Recently, bevacizumab in combination with the standard chemotherapy of 
carbolatin/paclitaxel was evaluated in two phase III trials demonstrating a significant 
improvement in PFS compared to the standard chemotherapy treatment (GOG 218 and 
ICON 7). Table 1 provides an overview of all published phase II and III studies (Table 1). 
Treating ovarian cancer patients with bevacizumab single agent regimens demonstrated 
very promising reponse rates (Table 1), furthermore some combined therapies including 
cytotoxic drugs seemed to enhance not only direct antitumoral efficacy but also 
antiangiogenic potentials. This is in particular the case for so called metronomic treatment 
strategies, where chemotherapeutic agents are administered in low dosages in regular, 
short time intervals, for example, cyclophosphamide in daily oral application (Sanchez-
Munoz et al., 2010).  
The main toxic effects of bevacizumab as documented in the available trials are 
hypertension, headache, proteinuria, thrombosis and hemoptysis (Table 1). A particular 
attention has been drawn on GI perforations that have been observed and seem to be a 
specific phenomenon on bevacizumab-therapies in patients with EOC. The exact 
pathomechanism of this potentially fatal complication is not fully understood though there 
are several explaining theories (Richardson et al., 2010). Currently, the average risk of 
developing a GI perforation during bevacizumab-therapy can be estimated at 7-8 % for 
patients with EOC (Richardson et al., 2010, Tanyi et al., 2011). 
VEGF trap 
VEGF trap (aflibercept®), a molecular fusion protein, inhibits VEGF-mediated events as a 
high affinity VEGF decoy. It is also able to bind to other VEGF familiy members e.g. PIGF. 
Tew et al. published a multicenter phase II study in women with recurrent ovarian cancer 
who were treated with 2mg/kg or 4mg/kg aflibercept, but the study only showed a 
moderate response rate (ORR 7 %, Moroney et al., 2009) 
Toxic effects of aflibercept are hypertension, headache, fatigue and GI –perforations (1,8%). 
Colombo et al. could show that aflibercept reduces ascites in patients with advanced ovarian 
cancer. They achieved a response in terms of less often repeated paracenteses. 
Ramucirumab 
Ramucirumab (IMC-1121B) is a novel fully human antibody targeting VEGFR2. It showed 
significant antitumor activity in several mouse tumors and human tumor xenografts by 
inhibiting angiogenesis mediated by reduction of microvessel density, tumor cell apoptosis 
and necrosis, as well as a decreased tumor cell proliferation (Prewett et al., 1999; Spratlin, 
2011). 
Ramucirumab is currently being explored in phase III trials in hepatocellular carcinomas 
(ImCLON HCC-Ramucirumab), NSCLC (Lilly study I4T-MC-JVB(a)), in previously 
untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast 
cancer (Trio-012) and in patients with metastatic colorectal carcinoma. A phase III study is 
designed in patients with metastatic adenocarcinoma of the stomach. The safety and efficacy 
of Ramucirumab is also evaluated in a randomized phase II trial in patients with metastatic 
melanoma with or without dacarbazine (Carvajal et al., 2010), as second-line therapy in 
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patients with locally advanced or metastatic transitional cell carcinoma of the bladder, 
urethra, ureter, or renal pelvis and metastatic androgen-independent prostate cancer with or 
without mitoxantrone and prednisone.  
At the time of publication, ramucirumab was undergoing assessment in a non-randomized, 
open-label, multicenter phase II study as a monotherapy  in the treatment of persistent or 
recurrent EOC, FTC, or PPC. Ramucirumab is given at 8mg/kg q2w. The results of these 
trials will tell whether ramucirumab is a useful addition to current antiangiogenic therapies 
and an option in the treatment of patients with ovarian cancer.  
Tyrosine kinase inhibitors 
Tyrosine kinase inhibitors repress the VEGF pathway by binding directly to the VEGFRs. 
Sorafenib 
Sorafenib is an oral tyrosine kinase inhibitor which not only targets VEGFR2 and 3 and 
PDGFR-beta but also the Ras/Raf/Mek/ERK pathways. In the GOG 170 trial Matei et al. 
evaluated Sorafenib as a single agent treatment in patients with recurrent ovarian cancer. In 
this phase II trial preliminary results showed a progression free survival for at least six 
months in 12 of 59 patients, partial response in 2 patients and stable disease in 20 patients. 
Progressive disease was determined in 30 patients (Matei et al., 2010). 
Siu et al. tested Sorafenib in combination with gemcitabine in a phase I trial in solid tumors 
and could show that the combination was well tolerated (Siu et al., 2006). In contrast to this 
and in line with Matei et al. Pölcher and colleagues pointed out that sorafenib showed 
markable toxicity in ovarian cancer study protocols, thus this drug needs to be further 
evaluated in clinical trials (Pölcher et al., 2010). 
Sunitinib 
Sunitinib (Sutent®) is also an oral tyrosine kinase inhibitor that binds to VEGFR 1-3 as well 
as PDGFR-alpha and beta. Sunitinib is approved for the treatment of advanced or metastatic 
renal cell carcinoma as first line therapy, of nonresectable gastrointestinal stromal tumours 
and for the treatment of patients with unresectable, locally advanced, or metastatic 
pancreatic neuroendocrine tumors (pNET). There a lots of clinical trials to determine the 
efficacy and safety of sunitinib in several tumor entities e.g glioblastoma, colon cancer and 
breast cancer. [http://clinicaltrialsfeeds.org/clinical-trials/results/term=sunitinib] 
In a preclinical study sunitinib inhibited tumor growth and reduced peritoneal metastasis of 
human ovarian cancer in xenografted mice. (Bauerschlag et al., 2010). The following phase II 
study of sunitinib (initial dose 50mg/d p.o) in 30 patients with recurrent EOC or PPC 
showed only a partial response (3,3%). Hand-foot-syndrome, hypertension, fatigue and 
gastrointestinal symptoms but no gastrointestinal perforation were the main toxicities. 
(Biagi et al.,  2011). 
Pazopanib 
Pazopanib is an investigational, oral, angiogenesis inhibitor targeting VEGFR, PDGFR and 
c-kit. Pazopanib is currently being studied in a number of different tumour types; clinical 
trials are currently underway in renal cell carcinoma (Phase III), breast cancer (Phase III in 
inflammatory breast cancer), ovarian cancer, STS, NSCLC, cervical cancer and other solid 
tumours. It is being evaluated as a monotherapy, in combination with targeted therapies 
and in combination with cytotoxic chemotherapy.  
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Table 2. Overview of published phase II and phase III trials on bevacizumab in patients with 
ovarian cancer. 
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VEG104450 is a Phase II study to assess the biochemical response rate (determined by CA-
125 response) to pazopanib monotherapy in subjects with epithelial ovarian, fallopian tube, 
or primary peritoneal carcinoma that have responded to standard treatment and who have a 
high risk of recurrence due to a rising CA-125. Data reported recently (Friedlander, 2008) 
showed that, in 36 ovarian subjects with biochemical (i.e. CA-125) recurrence after < 2 
treatment regimens, the most frequent AEs (reported by more than 20% of subjects) are 
diarrhoea, fatigue, nausea (all 47%), hypertension and abdominal pain (31%), AST and ALT 
increase (25%), anorexia and vomiting (22%). These were primarily Grade 1 and 2, with only 
one Grade 4 event reported in the study (of peripheral oedema, considered unrelated to the 
study drug); there were no Grade 5 events and no bowel perforations reported in this study. 
Currently, the German PACOVAR-trial analysis in a phase I/II setting evaluates activity 
and tolerability of pazopanib combined with orally administered metronomic 
cyclophosphamide in patients with recurrent, intensively pretreated ovarian cancer. First 
results of the phase I are expected in 2012. 
Endometrial cancer 
Endometrial cancer is the most common gynecologic malignancy with a peak incidence 
between the ages of 55 and 65. Worldwide about 142.000 women are affected by endometrial 
cancer every year (Jemal et al., 2010).  It is frequently diagnosed at an early stage as women 
affected often present by abnormal vaginal bleeding. At an early stage endometrial cancer 
can be treated surgically with curable intention (van Wijk et al., 2009).  In patients with high-
risk endometrial cancer postoperative pelvic radiotherapy, adjuvant radiation therapy or 
adjuvant chemotherapy have shown to improve outcome (Ray et al., 2009). 
However, about 13% of all patients with endometrial cancer develop recurrent disease. (Van 
Wijk et al., 2009). In the treatment of recurrent endometrial cancer different therapeutic 
modalities consisting of radiotherapy, surgery and systemic therapies as chemotherapy and 
hormone therapy are in use (Ray et al., 2009). Clinical trials evaluating chemotherapeutic 
regimen for patients with endometrial cancer include combinations of doxorubicin and 
cisplatin, cyclophosphamide or paclitaxel and carboplatin, most of them administered in 
palliative situation (Ray et al., 2009). 
Due to promising results of antiangiogenic treatment concepts in many solid tumors, some 
efforts have already been made to elucidate the role of VEGF in endometrial cancer. Kamat 
et al. examined serum samples of endometrial cancer patients and established an 
endometrioid orthotopic mouse model to approach the role of VEGF in endometrial cancer. 
The authors found significantly increased levels of VEGF in approximately half of the 
tumors. These high levels were independently associated with a poor outcome of the 
affected patients, as an overexpression of VEGF enhances tumor growth. Moreover, in a 
published mouse model study the combination of docetaxel and bevacizumab has proven a 
greater therapeutic efficacy than docetaxel or bevacizumab alone (Kamat et al., 2005). 
Recently, Aghajanian et al published data of a phase II GOG trial of bevacizumab in patients 
with recurrent or advanced endometrial cancer. In a series of n=56 patients the authors 
could demonstrate that a treatment regimen consisting of 15mg/kg bevacizumab i.v. every 
three weeks led to an ORR of 13.5% and a PFS at 6 months of 40.4% (Aghajanian et al., 2010). 
Furthermore, it could be shown that high VEGF-A immunohistochemical staining in 
archival tumors was associated with a reduced risk of death but that high circulating VEGF-
A levels were associated with poor outcome. For possible explanation authors suggested 
that VEGF staining in tumor did not reflect the state of the tumor before treatment when 
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VEGF-levels in plasma where measured. Finally, in 2011, Reinhardt and colleagues 
published a case report presenting the successful remission in a patient with recurrent, 
heavily pretreated endometrial cancer using a combination regimen with bevacizumab and 
metronomic cyclophosphamide (Reinhardt et al., 2011). Adverse events of bevacizumab 
therapies in endometrial cancer patients include GI-hemorrhage, proteinuria, hypertension, 
thrombosis and pulmonary embolism. So far no GI-perforations or fistulae have been 
reported (Aganajian et al., 2010) 
Beside bevacizumab as antiangiogenic treatment concept the oral tyrosine kinase inhibitors 
of multiple VEGF receptors sunitinib and sorafenib have been evaluated in clinical studies 
for the treatment of endometrial cancer. 
Sorafenib showed minimal activity with PFS at 6 months of 29% and median overall 
survival of 11.4 months. As adverse events hypertension, hand-foot-syndrome, anemia, 
thrombosis, fatigue and bleeding were found (Nimeiri et al., 2008). 
Accordingly, in a phase II study in recurrent or metastatic endometrial cancer  sunitinib 
demonstrated activity with an ORR of 15% and median overall survival of 19 months. 
Adverse events were fatigue and hypertension. (Correa et al., 2010) 
Cervical cancer 
Cervical cancer is the second most cause of female cancer mortality worldwide with 288 000 
deaths every year. About 510.000 cases of cervical cancer are reported each year with nearly 
80% in developing countries. Cervical cancer is preventable and generally curable if 
diagnosed at early stage (Wright et al., 2006). Surgery is the goldstandard in early lesions, 
whereas locally advanced lesions are managed with concurrent cisplatin chemotherapy and 
pelvic radiation (Monk et al., 2009). Metastatic disease or recurrent lesions not amenable to 
radical local excision or regional radiation are treated with palliative chemotherapy (Tewari 
et al., 2009). Patients diagnosed with locally advanced or metastatic cancer of the cervix have 
a very poor prognosis with a 5-year survival between 5 and 15 % (patients with stage IV 
disease) (Takano et al., 2009).  
Recurrent tumors within the irradiated and therefore devascularized fields likely have 
microenvironment changes that make chemotherapy delivery far from optimal. For these 
reasons, this patient population is not one that is ideally suited to receive multiple lines of 
chemotherapy. Biologic therapies offer another therapeutic strategy that has demonstrated 
effectiveness in tumors resistant to chemotherapy (Monk et al., 2010). 
Angiogenesis seems to play an important role in the development and progression of 
cervical cancer. Evidence that angiogenesis plays an important role in locally advanced 
cervical cancer has been shown in recent years (Mackay et al., 2010; Carpini et al., 2010). In 
one study of 111 patients with cervical cancer, Cooper et al identified tumor angiogenesis 
(as reflected by the tumor microvessel density) as a significant prognostic factor within a 
Cox multivariate analysis, where it was associated with poor locoregional control and 
overall survival.  Data from prospective studies in women with advanced cervical cancer, 
treated with anti-angiogenic therapy, are limited to a few small studies.  
Bevacizumab 
Corresponding to other solid tumors, most experiences are also reported in targeting VEGF 
with bevacizumab. 
Wright et al first evaluated the effect of the VEGF-Inhibitor bevacizumab in a retrospective 
trial in women with recurrent cervical cancer (Wright et al., 2006). Five patients were treated 
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with bevacizumab and 5-fluoruracil, one patient with bevacizumab and capecitabine, 
respectively. The median age of these patients was 43 years, the stage distribution was IB2, 
IIB and IIIB at 2 patients a throw. All of the patients had received  prior platinum-based 
chemotherapy. Bevacizumab was given intravenously every other week to five of the six 
patients with a starting dose of either 5 mg/kg or 10 mg/kg. One patient was given 
bevacizumab at a dose of 15 mg/kg every three weeks. A total of 30 doses of bevacizumab 
was given. The regimen was well tolerated. There was a grade 4 neutropenic sepsis 
encountered in one patient after 2 cycles of bevacizumab and one extremity thrombosis in 
another subject. The overall response rate (ORR) was 33 % (2 of the 6 patients). One of these 
patients showed a complete response, the other one a partial response. There was a stable 
disease in two patients (33 %). The median time to progression for the four patients with 
clinical benefit (CR, PR, SD) was 4.3 months. None of the patients demonstrated a 
progression free intervall > 6 months. Though only a small number of patients was 
observed, this study indicated that the combination of bevacizumab and 5-fluoruracil-based 
chemotherapy seems to be feasible and associated with significant activity in patients with 
recurrent cervical cancer. 
In 2009 Monk published a phase II-trial of bevacizumab in the treatment of persistent in 
recurrent squamous cell carcinoma of the cervix (GOG protocol 227C) (Monk et al., 2009). 
46 patients were randomized to the trial and received bevacizumab in a dose of 15 mg/kg 
intravenously every 3 weeks. Primary endpoints of the study were PFS for at least 6 months 
and evaluation of adverse events. A total of 254 cycles of bevacizumab as a single agent 
therapy were administered with a median of 4 cycles per patient. Eleven patients (23.9 %) 
experienced a progression free survival of > 6 months, whereas five patients (10.9 %) 
showed partial responses. Median overall survival for all patients was 7.29 months. There 
were several grade 3/ 4  adverse events demonstrated in this trial, including hypertension 
(n = 7), thromboembolism (n = 5), gastrointestinal complaints (n = 4), anemia (n = 2), vaginal 
bleeding (n = 1), neutropenia (n = 1) and fistula (n = 1) No unusual toxicities were noted. 
This trial provided that bevacizumab as a single agent therapy was relatively well tolerated, 
safe and demonstrated remarkable activity. Importantly, the results of this protocol 
constitute the first prospective clinical trial of a biologic agent that shows clinical activity in 
cervical cancer (Tewari et al., 2009). Exploratory analyses suggested an increased risk of 
progression (or death) for those who are African- American, are young, and have a poor 
performance status. Additional analyses also suggested an increased risk of death for those 
who have more prior chemotherapy regimens. 
Takano et al (Takano et al., 2009) reported of two cases of patients with cervical cancer 
treated with bevacizumab (2 mg/kg), paclitaxel (80 mg/m2) and carboplatin (AUC = 2.0). 
Therapy consisted of carboplatin/paclitaxel  weekly on days 1, 8, 15 and bevacizumab 
weekly on days 1, 8, 15, 21, q28d. In both patients full remission was notified and there was 
no evidence of disease for > 10 months as well as no adverse events higher than grade 3. 
Based on the findings in the studies described, a phase III trial with bevacizumab for 
treatment of cervical cancer is planned by the GOG. In GOG 240, patients will be 
randomized to one of four regimens: paclitaxel/cisplatin, paclitaxel/cisplatin plus 
bevacizumab, paclitaxel/topotecan and paclitaxel/topotecan plus bevacizumab. 
Also, other anti-angiogenesis compounds will soon be investigated by the GOG. For 
example, brivanib, a highly potent dual inhibitor of VEGFR and fibroblast growth factor 
receptor (FGFR) will be under study (Monk et al., 2010). 
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Sunitinib 
There is one phase II study published in 2010 by Mackay et al. that evaluates the activity of 
sunitinib, a tyrosine kinase inhibitor in the treatment of locally advanced or metastatic 
cervical cancer (Mackay et al., 2010) (NCIC CTG Trial IND.184). Sunitinib is an oral, multi-
targeted tyrosine kinase inhibitor, that inhibits receptors for VEGF, c-Kit and platelet-
derived growth factor. 19 patients received sunitinib at a dose of 50 mg/day in 6-week 
cycles (4 weeks, followed by 2 weeks off treatment). 16 patients (84 %) showed stable 
disease, but there was no objective response noted in any of the patients. However, 4 
patients developed fistulae during treatment and one patient had an enterocutaneous fistula 
3.5 months post-study. All of the fistulae occured within the previous radiation fields. 
Although SD-rate was 84 %, the overall progression free survival was only 3.5 months in 
this study, which compares with the progression free survival in the phase II trial published 
by Monk and described before. But the observation of five cases of  fistulae (26 %) was of 
particular concern, so that sunitinib as a single agent therapy does not have enough 
sufficient activity in women with advanced cervical cancer to recommend further study. 
3. Conclusion and future perspectives 
There is consensus that angiogenesis is a crucial phenomenon in the progression of 
gynecologic tumors. Many promising efforts have been made so far demonstrating that 
ovarian cancer as well as uterine cancers can be targeted by antiangiogenic treatment 
strategies. 
As gynecologic tumors still often respond very differently to antiangiogenic therapies future 
studies will have to work on identifying patients that will likely respond to specific 
antiangiogenic regimens. Existing and already proven active therapies will have to be 
confirmed in further long-term experiences, in particular regarding their potential long-
terms toxicity or side-effects and finally new, additional targets beyond the VEGF/ VEGFR-
mechanism have to be evaluated. Finally, a new attention should be paid to the concept of 
maintenance treatments, in particular in EOC, as antiangiogenic treatment concepts, might 
be especially useful in keeping a major cytotoxic therapeutic success. A particular role may 
be attributed in the future to combined antiangiogenic and metronomic cytotoxic regimens. 
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